our revenues will also depend upon the ability of aquabounty to establish successful commercialization of its aquadvantage® salmon products since it received regulatory approval in november 2015. our future revenues may also include additional revenue streams we may acquire through mergers and acquisitions . in light of our limited operating history and experience in consummating new collaborations and also the limited experience with our consolidated subsidiaries , there can be no assurance as to the timing , magnitude and predictability of revenues to which we might be entitled . cost of products and services cost of products and services includes primarily labor and related costs , drugs and supplies used primarily in the embryo transfer and in vitro fertilization processes , livestock and feed used in production , and facility charges , including rent and depreciation . fluctuations in the price of livestock and feed have not had a significant impact on our operating margins and no derivative financial instruments are used to mitigate the price risk . research and development expenses we recognize research and development expenses as they are incurred . our research and development expenses consist primarily of : salaries and benefits , including stock-based compensation expense , for personnel in research and development functions ; fees paid to consultants and contract research organizations who perform research on our behalf and under our direction ; costs related to laboratory supplies used in our research and development efforts ; costs related to certain in-licensed technology rights , including the costs to acquire and maintain technologies we licensed from md anderson in 2015 ; depreciation of leasehold improvements and laboratory equipment ; 46 amortization of patents and related technologies acquired in mergers and acquisitions ; and rent and utility costs for our research and development facilities . we have no individually significant research and development projects and our research and development expenses primarily relate to either the costs incurred to expand or otherwise improve our multiple platform technologies , the costs incurred to develop a specific application of our technologies in support of current or prospective collaborators , or costs incurred to expand or otherwise improve our products and services . research and development expenses , including costs for preclinical and clinical development , incurred for programs we support pursuant to an ecc agreement are typically reimbursed by the collaborator at cost and all other research and development programs may be terminated or otherwise deferred at our discretion . the amount of our research and development expenses may be impacted by , among other things , the number of eccs and the number and size of programs we may support on behalf of an ecc . the table below summarizes our research and development expenses incurred to expand or otherwise improve our multiple platform technologies , the costs incurred to develop a specific application of our technologies in support of current or prospective collaborators and licensees , or costs incurred to expand or otherwise improve our products and services for the years ended december 31 , 2015 , 2014 , and 2013 . other research and development expenses for these periods include indirect salaries and overhead expenses that are not allocated to either expanding or improving our multiple platform technologies , specific applications of our technologies in support of current or prospective collaborators and licensees , or expanding or improving our product and services offerings . replace_table_token_7_th we expect that our research and development expenses will increase as we continue to enter into collaborations and as we expand our offerings across additional market sectors . we believe these increases will likely include increased costs related to the hiring of additional personnel in research and development functions , increased costs paid to consultants and contract research organizations and increased costs related to laboratory supplies . research and development expenses may also increase as a result of ongoing research and development operations which we might assume through mergers and acquisitions . selling , general and administrative expenses selling , general and administrative expenses consist primarily of salaries and related costs , including stock-based compensation expense , for employees in executive , operational , finance , sales and marketing , information technology , legal and corporate communications functions . other significant selling , general and administrative expenses include rent and utilities , insurance , accounting and legal services and expenses associated with obtaining and maintaining our intellectual property . we expect that our selling , general and administrative expenses will increase as we continue to operate as a public company and expand our operations . we believe that these increases will likely include costs related to the hiring of additional personnel and increased fees for business development functions , outside consultants , lawyers and accountants , including costs to comply with corporate governance , internal controls and similar requirements applicable to public companies . selling , general and administrative expenses may also increase as a result of ongoing operations which we might assume through mergers and acquisitions . other income ( expense ) , net we hold equity securities received and or purchased from certain collaborators . other than investments accounted for using the equity method discussed below , we elected the fair value option to account for our equity securities held in these collaborators . these equity securities are recorded at fair value at each reporting date . unrealized appreciation ( depreciation ) resulting from fair value adjustments are reported as other income ( expense ) in the consolidated statement of operations . as such , we bear the 47 risk that fluctuations in the securities ' share prices may significantly impact our results of operations . in june 2015 , we recorded a realized gain related to the distribution of all our shares of ziopharm to our shareholders as a special stock dividend . interest income consists of interest earned on our cash and cash equivalents and short-term and long-term investments . story_separator_special_tag in conjunction with this ecc , we agreed to purchase additional common stock in a qualified financing , as defined in the agreement , during the sixteen months following the effective date of the ecc in an amount up to the lesser of ( i ) the amount that is the proportion of such financing equal to our pro rata equity holdings in oragenics as of the effective date and ( ii ) $ 10 million , subject to certain conditions . this amount is not included in the table above due to the uncertainty of when or if we will make this payment . in january 2015 , we and ziopharm jointly entered into a license agreement with md anderson whereby we received an exclusive license to certain technologies owned by md anderson . ziopharm will receive access to these technologies pursuant to the terms of our ecc . we and ziopharm are obligated to reimburse md anderson for out of pocket expenses for maintaining patents covering the licensed technologies . these reimbursements are not included in the table above due to the uncertainty of the timing and amounts of such reimbursements . in august 2014 , we acquired all of the membership interests of trans ova and agreed to pay a portion of certain cash proceeds in the event there is an award under certain litigation matters pending as of closing to which trans ova is a party . these amounts are not included in the table above due to the uncertainty of whether any amounts may be due . in conjunction with a prior transaction associated with trans ova 's subsidiary , viagen , in september 2012 , we may be obligated to make certain future contingent payments to the former equity holders of viagen , up to a total of $ 5.0 million if certain revenue targets , as defined in the share purchase agreement , are met . this amount is not included in the table above due to the uncertainty of when we will make any of these future payments , if ever . we acquired 100 percent of the outstanding capital stock of immunologix , inc. , or immunologix , in october 2011. the transaction included a contingent consideration arrangement which may require us to pay the selling shareholders 50 percent , subject to a maximum of $ 2.0 million , of revenue generated from immunologix 's technology applied towards a specific target 55 as defined in the agreement up to a maximum of $ 2.0 million . this amount is not included in the table above due to the uncertainty of whether , if ever , we will pay this contingent consideration . in january 2009 , aquabounty was awarded a grant to provide funding of a research and development project from the atlantic canada opportunities agency , a canadian government agency . amounts claimed by aquabounty must be repaid in the form of a 10 percent royalty on any products commercialized out of this research and development project until fully paid . because the timing of commercialization is subject to additional regulatory considerations , the timing of repayment is uncertain . aquabounty has claimed all amounts available under the grant , resulting in total long-term debt of $ 1.8 million on our consolidated financial statements as of december 31 , 2015 . this amount is not included in the table above due to the uncertainty of the timing of repayment . net operating losses as of december 31 , 2015 , we had net operating loss carryforwards of approximately $ 248.7 million for u.s. federal income tax purposes available to offset future taxable income and u.s. federal and state research and development tax credits of $ 6.8 million , prior to consideration of annual limitations that may be imposed under section 382. these carryforwards begin to expire in 2022 . our direct foreign subsidiaries have foreign loss carryforwards of approximately $ 109.7 million , most of which do not expire . our past issuances of stock and mergers and acquisitions have resulted in ownership changes within the meaning of section 382. as a result , the utilization of portions of our net operating losses may be subject to annual limitations . as of december 31 , 2015 , approximately $ 16.4 million of our domestic net operating losses generated prior to 2008 are limited by section 382 to annual usage limits of approximately $ 1.5 million . as of december 31 , 2015 , approximately $ 19.1 million of domestic net operating losses were inherited via acquisition and are limited based on the value of the target at the time of the transaction . future changes in stock ownership may also trigger an ownership change and , consequently , a section 382 limitation . we do not file a consolidated income tax return with aquabounty and biopop . as of december 31 , 2015 , aquabounty had loss carryforwards for federal and foreign income tax purposes of approximately $ 17.1 million and $ 10.9 million , respectively , and foreign research tax credits of $ 2.2 million available to offset future taxable income , prior to consideration of annual limitations that may be imposed under section 382 or analogous foreign provisions . these carryforwards will begin to expire in 2018 . as a result of our ownership in aquabounty passing 50 percent in 2013 , an annual section 382 limitation of approximately $ 0.9 million per year will apply to losses and credits carried forward by aquabounty from prior years , which are also subject to section 382 limitations . as of december 31 , 2015 , biopop had loss carryforwards of approximately $ 1.4 million for federal income tax purposes available to offset future taxable income . off-balance sheet arrangements we did not have during the periods presented , and we do not currently have , any off-balance sheet arrangements , other than operating leases as mentioned above , as

liquidity and capital resources sources of liquidity we have incurred losses from operations since our inception and as of december 31 , 2015 , we had an accumulated deficit of $ 542.7 million . from our inception through december 31 , 2015 , we have funded our operations principally with proceeds received from private and public offerings , cash received from our collaborators and through product and service sales made directly to customers . as of december 31 , 2015 , we had cash and cash equivalents of $ 135.8 million and short-term and long-term investments of $ 208.0 million . cash in excess of immediate requirements is invested primarily in money market funds , certificates of deposits and u.s. government debt securities in order to maintain liquidity and preserve capital . we currently generate cash receipts primarily from technology access fees , reimbursement of research and development services performed by us and sales of products and services . cash flows the following table sets forth the significant sources and uses of cash for the periods set forth below : replace_table_token_12_th cash flows from operating activities : net cash provided by operating activities was $ 35.7 million during the year ended december 31 , 2015 compared to $ 19.9 million net cash used in operating activities for the year ended december 31 , 2014. during the year ended december 31 , 2015 , we received net cash receipts for technology access fees of $ 85.5 million pursuant to new collaborations with ares trading , ziopharm , and intrexon energy partners ii . our net loss of $ 88.0 million , after deduction of noncash items of ( i ) $ 59.6 million of common stock issued to md anderson for the in-license of certain technologies , ( ii ) $ 38.7 million of stock-based compensation expense and ( iii ) $ 17.7 million of depreciation and amortization expense and the addition of $ 66.9 million of noncash unrealized and realized gains on our equity securities was $ 38.9 million .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources sources of liquidity we have incurred losses from operations since our inception and as of december 31 , 2015 , we had an accumulated deficit of $ 542.7 million . from our inception through december 31 , 2015 , we have funded our operations principally with proceeds received from private and public offerings , cash received from our collaborators and through product and service sales made directly to customers . as of december 31 , 2015 , we had cash and cash equivalents of $ 135.8 million and short-term and long-term investments of $ 208.0 million . cash in excess of immediate requirements is invested primarily in money market funds , certificates of deposits and u.s. government debt securities in order to maintain liquidity and preserve capital . we currently generate cash receipts primarily from technology access fees , reimbursement of research and development services performed by us and sales of products and services . cash flows the following table sets forth the significant sources and uses of cash for the periods set forth below : replace_table_token_12_th cash flows from operating activities : net cash provided by operating activities was $ 35.7 million during the year ended december 31 , 2015 compared to $ 19.9 million net cash used in operating activities for the year ended december 31 , 2014. during the year ended december 31 , 2015 , we received net cash receipts for technology access fees of $ 85.5 million pursuant to new collaborations with ares trading , ziopharm , and intrexon energy partners ii . our net loss of $ 88.0 million , after deduction of noncash items of ( i ) $ 59.6 million of common stock issued to md anderson for the in-license of certain technologies , ( ii ) $ 38.7 million of stock-based compensation expense and ( iii ) $ 17.7 million of depreciation and amortization expense and the addition of $ 66.9 million of noncash unrealized and realized gains on our equity securities was $ 38.9 million .
```    
 Suspicious Activity Report : our revenues will also depend upon the ability of aquabounty to establish successful commercialization of its aquadvantage® salmon products since it received regulatory approval in november 2015. our future revenues may also include additional revenue streams we may acquire through mergers and acquisitions . in light of our limited operating history and experience in consummating new collaborations and also the limited experience with our consolidated subsidiaries , there can be no assurance as to the timing , magnitude and predictability of revenues to which we might be entitled . cost of products and services cost of products and services includes primarily labor and related costs , drugs and supplies used primarily in the embryo transfer and in vitro fertilization processes , livestock and feed used in production , and facility charges , including rent and depreciation . fluctuations in the price of livestock and feed have not had a significant impact on our operating margins and no derivative financial instruments are used to mitigate the price risk . research and development expenses we recognize research and development expenses as they are incurred . our research and development expenses consist primarily of : salaries and benefits , including stock-based compensation expense , for personnel in research and development functions ; fees paid to consultants and contract research organizations who perform research on our behalf and under our direction ; costs related to laboratory supplies used in our research and development efforts ; costs related to certain in-licensed technology rights , including the costs to acquire and maintain technologies we licensed from md anderson in 2015 ; depreciation of leasehold improvements and laboratory equipment ; 46 amortization of patents and related technologies acquired in mergers and acquisitions ; and rent and utility costs for our research and development facilities . we have no individually significant research and development projects and our research and development expenses primarily relate to either the costs incurred to expand or otherwise improve our multiple platform technologies , the costs incurred to develop a specific application of our technologies in support of current or prospective collaborators , or costs incurred to expand or otherwise improve our products and services . research and development expenses , including costs for preclinical and clinical development , incurred for programs we support pursuant to an ecc agreement are typically reimbursed by the collaborator at cost and all other research and development programs may be terminated or otherwise deferred at our discretion . the amount of our research and development expenses may be impacted by , among other things , the number of eccs and the number and size of programs we may support on behalf of an ecc . the table below summarizes our research and development expenses incurred to expand or otherwise improve our multiple platform technologies , the costs incurred to develop a specific application of our technologies in support of current or prospective collaborators and licensees , or costs incurred to expand or otherwise improve our products and services for the years ended december 31 , 2015 , 2014 , and 2013 . other research and development expenses for these periods include indirect salaries and overhead expenses that are not allocated to either expanding or improving our multiple platform technologies , specific applications of our technologies in support of current or prospective collaborators and licensees , or expanding or improving our product and services offerings . replace_table_token_7_th we expect that our research and development expenses will increase as we continue to enter into collaborations and as we expand our offerings across additional market sectors . we believe these increases will likely include increased costs related to the hiring of additional personnel in research and development functions , increased costs paid to consultants and contract research organizations and increased costs related to laboratory supplies . research and development expenses may also increase as a result of ongoing research and development operations which we might assume through mergers and acquisitions . selling , general and administrative expenses selling , general and administrative expenses consist primarily of salaries and related costs , including stock-based compensation expense , for employees in executive , operational , finance , sales and marketing , information technology , legal and corporate communications functions . other significant selling , general and administrative expenses include rent and utilities , insurance , accounting and legal services and expenses associated with obtaining and maintaining our intellectual property . we expect that our selling , general and administrative expenses will increase as we continue to operate as a public company and expand our operations . we believe that these increases will likely include costs related to the hiring of additional personnel and increased fees for business development functions , outside consultants , lawyers and accountants , including costs to comply with corporate governance , internal controls and similar requirements applicable to public companies . selling , general and administrative expenses may also increase as a result of ongoing operations which we might assume through mergers and acquisitions . other income ( expense ) , net we hold equity securities received and or purchased from certain collaborators . other than investments accounted for using the equity method discussed below , we elected the fair value option to account for our equity securities held in these collaborators . these equity securities are recorded at fair value at each reporting date . unrealized appreciation ( depreciation ) resulting from fair value adjustments are reported as other income ( expense ) in the consolidated statement of operations . as such , we bear the 47 risk that fluctuations in the securities ' share prices may significantly impact our results of operations . in june 2015 , we recorded a realized gain related to the distribution of all our shares of ziopharm to our shareholders as a special stock dividend . interest income consists of interest earned on our cash and cash equivalents and short-term and long-term investments . story_separator_special_tag in conjunction with this ecc , we agreed to purchase additional common stock in a qualified financing , as defined in the agreement , during the sixteen months following the effective date of the ecc in an amount up to the lesser of ( i ) the amount that is the proportion of such financing equal to our pro rata equity holdings in oragenics as of the effective date and ( ii ) $ 10 million , subject to certain conditions . this amount is not included in the table above due to the uncertainty of when or if we will make this payment . in january 2015 , we and ziopharm jointly entered into a license agreement with md anderson whereby we received an exclusive license to certain technologies owned by md anderson . ziopharm will receive access to these technologies pursuant to the terms of our ecc . we and ziopharm are obligated to reimburse md anderson for out of pocket expenses for maintaining patents covering the licensed technologies . these reimbursements are not included in the table above due to the uncertainty of the timing and amounts of such reimbursements . in august 2014 , we acquired all of the membership interests of trans ova and agreed to pay a portion of certain cash proceeds in the event there is an award under certain litigation matters pending as of closing to which trans ova is a party . these amounts are not included in the table above due to the uncertainty of whether any amounts may be due . in conjunction with a prior transaction associated with trans ova 's subsidiary , viagen , in september 2012 , we may be obligated to make certain future contingent payments to the former equity holders of viagen , up to a total of $ 5.0 million if certain revenue targets , as defined in the share purchase agreement , are met . this amount is not included in the table above due to the uncertainty of when we will make any of these future payments , if ever . we acquired 100 percent of the outstanding capital stock of immunologix , inc. , or immunologix , in october 2011. the transaction included a contingent consideration arrangement which may require us to pay the selling shareholders 50 percent , subject to a maximum of $ 2.0 million , of revenue generated from immunologix 's technology applied towards a specific target 55 as defined in the agreement up to a maximum of $ 2.0 million . this amount is not included in the table above due to the uncertainty of whether , if ever , we will pay this contingent consideration . in january 2009 , aquabounty was awarded a grant to provide funding of a research and development project from the atlantic canada opportunities agency , a canadian government agency . amounts claimed by aquabounty must be repaid in the form of a 10 percent royalty on any products commercialized out of this research and development project until fully paid . because the timing of commercialization is subject to additional regulatory considerations , the timing of repayment is uncertain . aquabounty has claimed all amounts available under the grant , resulting in total long-term debt of $ 1.8 million on our consolidated financial statements as of december 31 , 2015 . this amount is not included in the table above due to the uncertainty of the timing of repayment . net operating losses as of december 31 , 2015 , we had net operating loss carryforwards of approximately $ 248.7 million for u.s. federal income tax purposes available to offset future taxable income and u.s. federal and state research and development tax credits of $ 6.8 million , prior to consideration of annual limitations that may be imposed under section 382. these carryforwards begin to expire in 2022 . our direct foreign subsidiaries have foreign loss carryforwards of approximately $ 109.7 million , most of which do not expire . our past issuances of stock and mergers and acquisitions have resulted in ownership changes within the meaning of section 382. as a result , the utilization of portions of our net operating losses may be subject to annual limitations . as of december 31 , 2015 , approximately $ 16.4 million of our domestic net operating losses generated prior to 2008 are limited by section 382 to annual usage limits of approximately $ 1.5 million . as of december 31 , 2015 , approximately $ 19.1 million of domestic net operating losses were inherited via acquisition and are limited based on the value of the target at the time of the transaction . future changes in stock ownership may also trigger an ownership change and , consequently , a section 382 limitation . we do not file a consolidated income tax return with aquabounty and biopop . as of december 31 , 2015 , aquabounty had loss carryforwards for federal and foreign income tax purposes of approximately $ 17.1 million and $ 10.9 million , respectively , and foreign research tax credits of $ 2.2 million available to offset future taxable income , prior to consideration of annual limitations that may be imposed under section 382 or analogous foreign provisions . these carryforwards will begin to expire in 2018 . as a result of our ownership in aquabounty passing 50 percent in 2013 , an annual section 382 limitation of approximately $ 0.9 million per year will apply to losses and credits carried forward by aquabounty from prior years , which are also subject to section 382 limitations . as of december 31 , 2015 , biopop had loss carryforwards of approximately $ 1.4 million for federal income tax purposes available to offset future taxable income . off-balance sheet arrangements we did not have during the periods presented , and we do not currently have , any off-balance sheet arrangements , other than operating leases as mentioned above , as

